# A Study of KL590586 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05265091/  
OnCo record `nct05265091` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of KL590586 Capsule in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of KL590586 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05265091 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 414 participants enrolled, started 2021-09-15 and due to reach its primary completion in 2026-12-31. Interventions recorded: KL590586 Capsule.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05265091
- Phase: 1/2
- Setting: An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 414

## Sources

- ClinicalTrials.gov NCT05265091: https://clinicaltrials.gov/study/NCT05265091

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05265091.json